Providence Cancer Institute’s commitment to advancing immunotherapy research and clinical trials is, again, making a difference in the lives of cancer patients at home and around the world.
We were one of the first sites, internationally, to open a clinical trial of the immunotherapy drug Atezolizumab combined with a common chemotherapy for patients with metastatic triple negative breast cancer – a very deadly and aggressive form of the disease.
One of our first patients to join the trial more than three years ago continues in treatment today. Her oncologist, Dr. Alison Conlin, says Eva Joseph’s bone and lung tumors have shrunk dramatically and she is doing very well.
The success of this trial, thanks in part to patients such as Eva, has led the FDA to accelerate the approval of the first immunotherapy drug for breast cancer.
We are able to offer this and other groundbreaking clinical trials because of Providence Cancer Institute’s international reputation in immunotherapy research.
